Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03884166
Other study ID # MUCINS
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 30, 2021
Est. completion date December 31, 2022

Study information

Verified date March 2022
Source Charite University, Berlin, Germany
Contact Andreas Meisel, Prof. Dr. med.
Phone +49 30 450 560026
Email andreas.meisel@charite.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Stroke patients frequently suffer from stroke associated pneumonia. Pathophysiologically speaking, dysphagia and central nervous system (CNS)-injury induced immunosuppression largely contribute to the risk for pneumonia. In mouse models for stroke, the self-cleaning mechanisms of the lung are also affected by stroke, possibly further contributing to this risk. The investigators designed a pilot-study to examine the structural and functional integrity of the self-cleaning mechanisms of the lung in stroke patients.


Description:

Survival and functional outcome of stroke is strongly depending on the occurence of pneumonia (stroke-associated pneumonia, SAP). Early diagnose and treatment of SAP is paramount in the treatment of stroke patients. While dysphagia strongly contributes to its pathogenesis, recent years have also shown a strong risk-modulation by CNS injury induced immunosuppression, making stroke patients more susceptible to SAP. Additionally, murine models of stroke showed changes in mucociliary clearance as possible contributors to SAP. It remains unclear, whether structural integrity and mucociliary clearance of the respiratory epithel change in stroke patients, and whether these changes might contribute to the occurence of SAP. Therefore, the investigators designed this exploratory observational pilot-study to examine the structural and functional integrity of respiratory epithel in severely affected stroke patients and correlate these findings to immune phenotyping and occurence of SAP. The investigators will conduct bronchoscopy in severely affected stroke patients to collect histological samples in order to evaluate multiple tissue predictors, as well as perform optical coherence tomography to examine ciliary kinetics in-vivo. The investigators will furthermore perform serum and plasma immune phenotyping, record occuring pneumonias and correlate these data in order to identify possible predictors of pneumonia.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 31, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Informed consent signed by patient or legal representatives - Acute ischemic stroke within the past 2 weeks (except the control group) - Indication for diagnostic or therapeutic bronchoscopy Exclusion Criteria: - Confirmed lung malignancies or specific inflammations of the lungs - Pneumonia (only control group) - Autoimmune diseases of respiratory system (only control group) - Chronic inflammatory diseases of respiratory system (only control group) - chronic obstructive pulmonary disease (COPD) and spastic diseases of respiratory system (only control group) - Patients being committed to psychiatric institutions or prisons

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
bronchoscopy
Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance

Locations

Country Name City State
Germany NeuroCure Clinical Research Center (NCRC), Charité Berlin-Mitte

Sponsors (6)

Lead Sponsor Collaborator
Charite University, Berlin, Germany Department of Infectiology and Pneumonology, Charite, Berlin, Labor Berlin - Charité Vivantes GmbH, NeuroCure Clinical Research Center, Charite, Berlin, University of Giessen, University of Luebeck

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mucociliary Clearance - number of cilia (scanning electron microscopy) at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Primary Mucociliary Clearance - activity of cilia given as frequency (in-vivo optical coherence tomography) at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Secondary Occurence of stroke-associated pneumonia Pneumonia is defined according to the consensus recommendations (Smith et al., Stroke 2015) 7 days after stroke
Secondary Activity of autonomous nervous system Concentration of Cortisol, Adrenaline and Noradrenaline in blood and heart frequency variability at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Secondary Activity of immune System - Concentration of cytokines Concentration of cytokines (IL-6, IL-13 and more) in blood at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Secondary Activity of immune System - Concentration of inflammatory markers Concentration of inflammatory markers (PCT, CRP) in blood at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Secondary Activity of immune System - Expression of HLA-DR Expression of Human Leukocyte Antigens (HLA)-DR on monocytes in antigens/cell at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Secondary Structural changes in respiratory tissue (nasal, tracheal and bronchial) - Autophagy Intensity of fluorescence of Light chain (LC) 3b protein, Aurora A and Human enhancer of filamentation (HEF)1 at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Secondary Structural changes in respiratory tissue (nasal, tracheal and bronchial) - Apoptosis Intensity of fluorescence of TUNEL at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
Secondary Structural changes in respiratory tissue (nasal, tracheal and bronchial) - Increase of secretory cells Expression levels of surfactant protein, Muc5a, SPDEF, Foxa3 at time of bronchoscopy (within 2 weeks after acute ischemic stroke)
See also
  Status Clinical Trial Phase
Recruiting NCT03993236 - Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke Phase 4
Completed NCT04069767 - Innovative Physiotherapy in Stroke Rehabilitation N/A
Recruiting NCT06342206 - The Assessment of Acute /Chronic Phase in Patients With Ischemic Cerebral Stroke Using TCM Diagnostic Tools
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Enrolling by invitation NCT04956211 - Periodontal Treatment and Ischemic Stroke N/A
Active, not recruiting NCT05098236 - Effect of Visual Retraining on Visual Loss Following Visual Cortical Damage N/A
Completed NCT03942588 - High-intensity Interval Training After Stroke N/A
Recruiting NCT04949334 - Effects of Respiratory Muscle Training in Patients With Acute Ischemic Stroke N/A
Terminated NCT04095767 - Assessing Safety and Performance of the ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke N/A
Not yet recruiting NCT06352086 - Understanding Visual Processing After Occipital Stroke
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Completed NCT01937182 - The Efficacy of Citalopram Treatment in Acute Stroke Phase 2
Completed NCT03649295 - Combined Conventional Speech Therapy and Functional Electrical Stimulation in Dysphagia Following Stroke N/A
Recruiting NCT05303649 - Effects of Neuronavigated Theta Burst Stimulation in Therapy of Post-stroke Aphasia N/A
Completed NCT04233515 - Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County
Completed NCT05102877 - Sensory Versus Motor Level Neuromuscular Electrical Stimulation N/A
Completed NCT04089917 - A Study of the Use of the Q Aspiration Catheter to Remove Clot in Stroke Patients
Completed NCT05221112 - Effects of PNF Patterns Training on Trunk Balance, and Gait in Chronic Stroke Patients N/A
Not yet recruiting NCT05035953 - Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke Phase 2
Completed NCT06326801 - Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise in Sub-acute Stroke Patients N/A